December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Benjamin Ebert: Honored to begin my tenure as President and CEO of Dana-Farber Cancer Institute
Oct 3, 2024, 17:56

Benjamin Ebert: Honored to begin my tenure as President and CEO of Dana-Farber Cancer Institute

Benjamin Ebert shared a post on LinkedIn:

“I am honored to begin my tenure today as President and CEO of Dana-Farber Cancer Institute.

This is an exciting time for our institution, as we continue planning for our proposed future hospital dedicated entirely to patients with cancer and our collaboration with Beth Israel Deaconess Medical Center. We are well positioned to continue as a leader in innovation and in caring and advocating for patients of all ages and from all communities.

And just as we always have, we remain rooted by our unrelenting focus on research and our pursuit of new discoveries that can change how cancer is treated for patients everywhere.

What makes this possible, and the reason I am so excited, is because of our Dana-Farber community. The opportunity to work with outstanding leaders, clinicians, researchers, and professionals across the Institute makes this an incredibly special place to work. I am honored to work toward our mission alongside each of you.”

Benjamin Ebert: Honored to begin my tenure as President and CEO of Dana-Farber Cancer Institute

Source: Benjamin Ebert/LinkedIn

More posts featuring Benjamin Ebert on oncodaily.com

The New President and CEO of Dana-Farber Cancer Center – Benjamin Ebert

Benjamin L. Ebert is the President and CEO of Dana-Farber Cancer Institute. He is also George P. Canellos Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator and an Institute Member of the Broad Institute.

Ebert, a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians, focuses on the molecular basis and treatment of hematologic malignancies, especially myelodysplastic syndromes (MDS).